2-(1H-benzo[d]imidazol-1-yl)-9-(tetrahydro-2H-pyran-4-yl)-7H-purin-8(9H)-one | 1083299-77-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-(1H-benzo[d]imidazol-1-yl)-9-(tetrahydro-2H-pyran-4-yl)-7H-purin-8(9H)-one
• 英文别名: 2-(benzimidazol-1-yl)-9-(oxan-4-yl)-7H-purin-8-one
• CAS: 1083299-77-7
• 化学式: C₁₇H₁₆N₆O₂
• 分子量: 336.353
• InChiKey: WURORWMCWDGYBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  85.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  、 N,N'-羰基二咪唑 以 二氯甲烷 为溶剂， 生成 2-(1H-benzo[d]imidazol-1-yl)-9-(tetrahydro-2H-pyran-4-yl)-7H-purin-8(9H)-one
  参考文献：
  名称：

  2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors

  摘要：

  A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described. Through substitution of the benzimidazoyl moiety and optimization of the N-9 substituent of the purinone, compound 24 was identified incorporating a chroman-based functional group. Compound 24 shows excellent kinase activity, good oral bioavailability and demonstrates efficacy in an acute mechanistic mouse model through inhibition of interleukin-2 (IL-2) induced interferon-gamma (INF-gamma) production. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.080

文献信息

• Purine and imidazopyridine derivatives for immunosuppression
  申请人：Ohlmeyer J. Michael

  公开号：US20070021443A1

  公开（公告）日：2007-01-25

  The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas:

  本发明提供了新型嘌呤和咪唑吡啶衍生物，可用于预防和治疗自身免疫性疾病、炎症性疾病、肥大细胞介导疾病和移植排斥。这些化合物的一般式如下：
• PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION
  申请人：Ohlmeyer Michael J.

  公开号：US20080287468A1

  公开（公告）日：2008-11-20

  The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas:

  本发明提供了新型嘌呤和咪唑吡啶衍生物，用于预防和治疗自身免疫性疾病、炎症性疾病、肥大细胞介导的疾病和移植排斥。这些化合物的一般式如下：
• US7884109B2
  申请人：——

  公开号：US7884109B2

  公开（公告）日：2011-02-08
• 2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors
  作者：Andrew G. Cole、Adolph C. Bohnstedt、Vidyadhar Paradkar、Celia Kingsbury、Jorge G. Quintero、Haengsoon Park、Yingchun Lu、Ming You、Irina Neagu、David J. Diller、Jeffrey J. Letourneau、Yuefei Shao、Ray A. James、Christopher M. Riviello、Koc-Kan Ho、Tsung H. Lin、Bojing Wang、Kenneth C. Appell、Matthew Sills、Elizabeth Quadros、Earl F. Kimble、Michael H.J. Ohlmeyer、Maria L. Webb

  DOI：10.1016/j.bmcl.2009.09.080

  日期：2009.12

  A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described. Through substitution of the benzimidazoyl moiety and optimization of the N-9 substituent of the purinone, compound 24 was identified incorporating a chroman-based functional group. Compound 24 shows excellent kinase activity, good oral bioavailability and demonstrates efficacy in an acute mechanistic mouse model through inhibition of interleukin-2 (IL-2) induced interferon-gamma (INF-gamma) production. (C) 2009 Elsevier Ltd. All rights reserved.